Neos Therapeutics Inc. (NASDAQ:NEOS) was up 4% during trading on Monday . The stock traded as high as $8.89 and last traded at $8.89, with a volume of 87,665 shares traded. The stock had previously closed at $8.55.

Several equities research analysts have commented on NEOS shares. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Thursday, April 21st. BMO Capital Markets started coverage on Neos Therapeutics in a research note on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Royal Bank Of Canada dropped their price target on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, May 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $21.75.

The company’s market capitalization is $145.37 million. The stock’s 50 day moving average price is $9.63 and its 200-day moving average price is $9.94.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.08. Equities research analysts expect that Neos Therapeutics Inc. will post ($4.88) EPS for the current year.

In related news, Director Alan L. Heller acquired 10,000 shares of the firm’s stock in a transaction on Thursday, May 19th. The shares were bought at an average cost of $7.61 per share, with a total value of $76,100.00. Following the completion of the acquisition, the director now owns 379,888 shares of the company’s stock, valued at $2,890,947.68. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gregory J. Robitaille acquired 7,442 shares of the firm’s stock in a transaction on Wednesday, May 18th. The shares were bought at an average cost of $7.55 per share, for a total transaction of $56,187.10. Following the completion of the acquisition, the director now directly owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP increased its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.